| METHOD FOR PREDICTION OF LEUKOCYTE TELOMERE LENGTH WITH UNDERLYING SEX STEROID REPLACEMENT THERAPY IN PATIENTS WITH TURNER SYNDROME OR PREMATURE OVARIAN FAILURE | |
| 2024-03-15 | |
| 专利权人 | FEDERAL STATE BUDGETARY INST (FSBI-C) |
| 申请日期 | 2024-03-15 |
| 专利号 | RU2827907-C1 |
| 成果简介 | NOVELTY - Group of inventions relates to medicine, namely to endocrinology, obstetrics and gynaecology, gerontology, and can be used to predict telomere length (ZTelomere length pred, kb) with the underlying sex steroid replacement therapy in the cyclic regimen in the patients with Turner syndrome or premature ovarian failure and the evaluation of the efficacy of the sex steroid replacement therapy in the cyclic regimen in the patients. Following parameters are determined: predicted duration of hormone replacement therapy (HRT) with sex steroids (Xtaking HRT, years), basal telomere length (YTelomere length basal, kb) at the moment of menopause. Value of ZTelomere length pred is calculated using the formula: ZTelomere length pred = 0.216 × Xtaking HRT + YTelomere length basal + 9.49. Basal telomere length (YTelomere length basal, kb) can be determined as the arithmetic mean between leukocyte telomere length calculated by real-time quantitative PCR and leukocyte telomere length calculated by cytogenetic fluorescent hybridisation in situ. When assessing the effectiveness of the sex steroid replacement therapy in the cyclic mode in the patients with Turner syndrome or premature ovarian failure, telomere length is determined (YTelomere length, kb) at the evaluation date through Xtaking HRT years and comparison with the predicted telomere length on the date of starting HRT using the duration of Xtaking HRT years (ZTelomere length pred, kb). If YTelomere length is higher, identical or less than 15% lower ZTelomere length pred, then therapy is considered effective. If YTelomere length is 15% or lower than ZTelomere length pred, then the therapy is considered to be ineffective and the woman is referred to a geriatrician for the correction of the therapy. Telomere length (YTelomere length, kb) can be determined as the arithmetic mean between leukocyte telomere length calculated by real-time quantitative PCR and leukocyte telomere length calculated by cytogenetic fluorescent hybridisation in situ. Comparison with predicted telomere length (ZTelomere length pred, kb) can be carried out once year for 5 years after the onset of menopause and the beginning of the sex steroid replacement therapy in a cyclic mode. USE - Medicine. ADVANTAGE - Method provides the possibility of predicting the replicative cell potential – leukocyte telomere length in the patients with Turner syndrome or premature ovarian failure, who have not previously taken HRT, in order to prevent age-associated diseases of a person, by assessing the target personalized indicator of the effectiveness of taking HRT at the initial point – the moment of initiation of HRT, and the end point is 5 years from the moment of HRT initiation, with monitoring frequency once a year by venous sampling and laboratory analysis of the patient’s biological material. 5 cl, 2 ex |
| IPC 分类号 | C12Q-001/6841 ; C12Q-001/6851 ; C12Q-001/686 ; C12Q-001/6883 ; G01N-033/49 |
| 国家 | 俄罗斯 |
| 专业领域 | 生物科学 |
| 语种 | 英语 |
| 成果类型 | 专利 |
| 文献类型 | 科技成果 |
| 条目标识符 | http://119.78.100.226:8889/handle/3KE4DYBR/17696 |
| 专题 | 中国科学院新疆生态与地理研究所 |
| 作者单位 | FEDERAL STATE BUDGETARY INST (FSBI-C) |
| 推荐引用方式 GB/T 7714 | MIKHEEV R K,MELNICHENKO G A,ANDREEVNA E N,et al. METHOD FOR PREDICTION OF LEUKOCYTE TELOMERE LENGTH WITH UNDERLYING SEX STEROID REPLACEMENT THERAPY IN PATIENTS WITH TURNER SYNDROME OR PREMATURE OVARIAN FAILURE. RU2827907-C1[P]. 2024. |
| 条目包含的文件 | 条目无相关文件。 | |||||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论